If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> EUROPEAN MEDICAL JOURNAL<br /> ISSN 2397-6764 Vol 3.3 • September 2018 • europeanmedical-journal.com<br /> Contents<br /> EDITORIAL BOARD 4<br /> WELCOME 7<br /> FOREWORD 9<br /> 01 ARTICLES<br /> Editor’s Pick: Chimeric Antigen Receptor-Engineered T Cell Therapy 11<br /> in Acute Myeloid Leukaemia<br /> Etienne Paubelle et al.<br /> Adherence During Early Allergen Immunotherapy and Strategies 21<br /> to Motivate and Support Patients<br /> Natalija Novak et al.<br /> Interim Results of the Basket of Real-World Randomi<a title="EMJ 3.3 2018 page 1" href="http://viewer.zmags.com/publication/cc59823c?page=1"> EUROPEAN MEDICAL JOURNAL ISSN 2397-6764 </a> <a title="EMJ 3.3 2018 page 2" href="http://viewer.zmags.com/publication/cc59823c?page=2"> Contents EDITORIAL BOARD </a> <a title="EMJ 3.3 2018 page 3" href="http://viewer.zmags.com/publication/cc59823c?page=3"> "...our flagship journal melds articles from a var</a> <a title="EMJ 3.3 2018 page 4" href="http://viewer.zmags.com/publication/cc59823c?page=4"> Editorial Board Editor-in-Chief Prof Markus Peck-</a> <a title="EMJ 3.3 2018 page 5" href="http://viewer.zmags.com/publication/cc59823c?page=5"> Aims and Scope The European Medical Journal (EMJ)</a> <a title="EMJ 3.3 2018 page 6" href="http://viewer.zmags.com/publication/cc59823c?page=6"> EMJ 3.3 Chief Executive Officer Spencer Gore Seni</a> <a title="EMJ 3.3 2018 page 7" href="http://viewer.zmags.com/publication/cc59823c?page=7"> Welcome Hello and welcome. It is my great pleasur</a> <a title="EMJ 3.3 2018 page 8" href="http://viewer.zmags.com/publication/cc59823c?page=8"> Raise Your EXPECTATIONS This advert is int</a> <a title="EMJ 3.3 2018 page 9" href="http://viewer.zmags.com/publication/cc59823c?page=9"> Foreword Dear colleagues and friends, I am very p</a> <a title="EMJ 3.3 2018 page 10" href="http://viewer.zmags.com/publication/cc59823c?page=10"> RESPIRATORY ULTRASOUND The evidence is compelling</a> <a title="EMJ 3.3 2018 page 11" href="http://viewer.zmags.com/publication/cc59823c?page=11"> Chimeric Antigen Receptor-Engineered T Cell </a> <a title="EMJ 3.3 2018 page 12" href="http://viewer.zmags.com/publication/cc59823c?page=12"> INTRODUCTION Acute myeloid leukaemia (AML) is an </a> <a title="EMJ 3.3 2018 page 13" href="http://viewer.zmags.com/publication/cc59823c?page=13"> diffuse large B cell lymphoma and ALL.20-27</a> <a title="EMJ 3.3 2018 page 14" href="http://viewer.zmags.com/publication/cc59823c?page=14"> Table 1: Current clinical trials using chimeric a</a> <a title="EMJ 3.3 2018 page 15" href="http://viewer.zmags.com/publication/cc59823c?page=15"> T cells directed against LeY in four AML patients</a> <a title="EMJ 3.3 2018 page 16" href="http://viewer.zmags.com/publication/cc59823c?page=16"> of this family share a common protein fold and ha</a> <a title="EMJ 3.3 2018 page 17" href="http://viewer.zmags.com/publication/cc59823c?page=17"> alloHSCT as well as new targeted therapies.</a> <a title="EMJ 3.3 2018 page 18" href="http://viewer.zmags.com/publication/cc59823c?page=18"> 30. Turatti F et al. Redirected activity of </a> <a title="EMJ 3.3 2018 page 19" href="http://viewer.zmags.com/publication/cc59823c?page=19"> determinants of Lewis system 77. </a> <a title="EMJ 3.3 2018 page 20" href="http://viewer.zmags.com/publication/cc59823c?page=20"> YOUR EXPERT PAR FOR HOME HEM TNER ODIALYSIS </a> <a title="EMJ 3.3 2018 page 21" href="http://viewer.zmags.com/publication/cc59823c?page=21"> Adherence During Early Allergen Immunotherapy and</a> <a title="EMJ 3.3 2018 page 22" href="http://viewer.zmags.com/publication/cc59823c?page=22"> eHealth reminders via a telephone call, text mess</a> <a title="EMJ 3.3 2018 page 23" href="http://viewer.zmags.com/publication/cc59823c?page=23"> provider, thereby improving cost-effectiveness</a> <a title="EMJ 3.3 2018 page 24" href="http://viewer.zmags.com/publication/cc59823c?page=24"> ALLERGEN IMMUNOTHERAPY CONTINUATION RATES WITH A</a> <a title="EMJ 3.3 2018 page 25" href="http://viewer.zmags.com/publication/cc59823c?page=25"> AIT discontinuers (i.e., those who stopped t</a> <a title="EMJ 3.3 2018 page 26" href="http://viewer.zmags.com/publication/cc59823c?page=26"> to other settings or systems. Idea</a> <a title="EMJ 3.3 2018 page 27" href="http://viewer.zmags.com/publication/cc59823c?page=27"> A retrospective analysis conducted in patients wi</a> <a title="EMJ 3.3 2018 page 28" href="http://viewer.zmags.com/publication/cc59823c?page=28"> CONCLUSION AIT is the only treatment for AR and a</a> <a title="EMJ 3.3 2018 page 29" href="http://viewer.zmags.com/publication/cc59823c?page=29"> 5-grass-pollen sublingual </a> <a title="EMJ 3.3 2018 page 30" href="http://viewer.zmags.com/publication/cc59823c?page=30"> Interim Results of the Basket of Real-World Ra</a> <a title="EMJ 3.3 2018 page 31" href="http://viewer.zmags.com/publication/cc59823c?page=31"> thrombosis. However, the difference was not stati</a> <a title="EMJ 3.3 2018 page 32" href="http://viewer.zmags.com/publication/cc59823c?page=32"> present in the native epicardial corona</a> <a title="EMJ 3.3 2018 page 33" href="http://viewer.zmags.com/publication/cc59823c?page=33"> level α=0.005, to measure any differenc</a> <a title="EMJ 3.3 2018 page 34" href="http://viewer.zmags.com/publication/cc59823c?page=34"> In-segment analysis of the SES and EES groups rev</a> <a title="EMJ 3.3 2018 page 35" href="http://viewer.zmags.com/publication/cc59823c?page=35"> E 0 Sirolimus Everolimus </a> <a title="EMJ 3.3 2018 page 36" href="http://viewer.zmags.com/publication/cc59823c?page=36"> and EES; but the incidence was raised to 10 and 4</a> <a title="EMJ 3.3 2018 page 37" href="http://viewer.zmags.com/publication/cc59823c?page=37"> more recurrent after implantation of EES than aft</a> <a title="EMJ 3.3 2018 page 38" href="http://viewer.zmags.com/publication/cc59823c?page=38"> randomised non-inferiority trial. Lancet. 2008;37</a> <a title="EMJ 3.3 2018 page 39" href="http://viewer.zmags.com/publication/cc59823c?page=39"> IDIYDLLA TM MSI ASSAY YLL A NEW ERA</a> <a title="EMJ 3.3 2018 page 40" href="http://viewer.zmags.com/publication/cc59823c?page=40"> Alcohol or Not: A Review Comparing Initial Mech</a> <a title="EMJ 3.3 2018 page 41" href="http://viewer.zmags.com/publication/cc59823c?page=41"> INTRODUCTION Alcohol-related liver disease </a> <a title="EMJ 3.3 2018 page 42" href="http://viewer.zmags.com/publication/cc59823c?page=42"> and cause damage to hepatocytes through lyso</a> <a title="EMJ 3.3 2018 page 43" href="http://viewer.zmags.com/publication/cc59823c?page=43"> Oxidative stress could increase the generation of</a> <a title="EMJ 3.3 2018 page 44" href="http://viewer.zmags.com/publication/cc59823c?page=44"> known risk for developing ALD: among people who </a> <a title="EMJ 3.3 2018 page 45" href="http://viewer.zmags.com/publication/cc59823c?page=45"> Table 2: Outcome of liver transplantation for non</a> <a title="EMJ 3.3 2018 page 46" href="http://viewer.zmags.com/publication/cc59823c?page=46"> Table 3: Outcome of liver transplantation for alc</a> <a title="EMJ 3.3 2018 page 47" href="http://viewer.zmags.com/publication/cc59823c?page=47"> steatohepatitis probably have traits of both</a> <a title="EMJ 3.3 2018 page 48" href="http://viewer.zmags.com/publication/cc59823c?page=48"> Exp Res. 1981;5(2):207-15. 35. Struben VM et al.</a> <a title="EMJ 3.3 2018 page 49" href="http://viewer.zmags.com/publication/cc59823c?page=49"> Recent Updates on Corticosteroid Resi</a> <a title="EMJ 3.3 2018 page 50" href="http://viewer.zmags.com/publication/cc59823c?page=50"> Resistance to steroids has also been reported in </a> <a title="EMJ 3.3 2018 page 51" href="http://viewer.zmags.com/publication/cc59823c?page=51"> Multiple promoters Promoter 1A Promoter 1B </a> <a title="EMJ 3.3 2018 page 52" href="http://viewer.zmags.com/publication/cc59823c?page=52"> A Corticosteroids B Cytoplasm Cellular processes</a> <a title="EMJ 3.3 2018 page 53" href="http://viewer.zmags.com/publication/cc59823c?page=53"> Once GR enters the nucleus, the activated h</a> <a title="EMJ 3.3 2018 page 54" href="http://viewer.zmags.com/publication/cc59823c?page=54"> Defective Glucocorticoid Receptor Binding and Nuc</a> <a title="EMJ 3.3 2018 page 55" href="http://viewer.zmags.com/publication/cc59823c?page=55"> Table 1: List of possible drugs and novel therape</a> <a title="EMJ 3.3 2018 page 56" href="http://viewer.zmags.com/publication/cc59823c?page=56"> to increase the expression of HDAC2 and red</a> <a title="EMJ 3.3 2018 page 57" href="http://viewer.zmags.com/publication/cc59823c?page=57"> 18. Ausiello D et al. Pathogenesis of gout. </a> <a title="EMJ 3.3 2018 page 58" href="http://viewer.zmags.com/publication/cc59823c?page=58"> Diagnostic Accuracy of Magnetic Resonance C</a> <a title="EMJ 3.3 2018 page 59" href="http://viewer.zmags.com/publication/cc59823c?page=59"> The sensitivity, specificity, and positive and neg</a> <a title="EMJ 3.3 2018 page 60" href="http://viewer.zmags.com/publication/cc59823c?page=60"> Table 1: Number of patients identified with common</a> <a title="EMJ 3.3 2018 page 61" href="http://viewer.zmags.com/publication/cc59823c?page=61"> descriptive statistics and reported as mean and s</a> <a title="EMJ 3.3 2018 page 62" href="http://viewer.zmags.com/publication/cc59823c?page=62"> Table 3: Laboratory findings in patients with norm</a> <a title="EMJ 3.3 2018 page 63" href="http://viewer.zmags.com/publication/cc59823c?page=63"> group (mean difference: 253.6 U/L; 95% CI: </a> <a title="EMJ 3.3 2018 page 64" href="http://viewer.zmags.com/publication/cc59823c?page=64"> Table 4: Average values of laboratory findings in </a> <a title="EMJ 3.3 2018 page 65" href="http://viewer.zmags.com/publication/cc59823c?page=65"> OPTIMIZING TAVI ACURATE neo's unique self-expand</a> <a title="EMJ 3.3 2018 page 66" href="http://viewer.zmags.com/publication/cc59823c?page=66"> Systemic Expression of Oxidative DNA Damage and A</a> <a title="EMJ 3.3 2018 page 67" href="http://viewer.zmags.com/publication/cc59823c?page=67"> those without AGD (0.79±0.11 ng/mL; p=0.121) and </a> <a title="EMJ 3.3 2018 page 68" href="http://viewer.zmags.com/publication/cc59823c?page=68"> recipients with renal comorbidities at the time o</a> <a title="EMJ 3.3 2018 page 69" href="http://viewer.zmags.com/publication/cc59823c?page=69"> a Mann–Whitney U test was used. Chi-squared was </a> <a title="EMJ 3.3 2018 page 70" href="http://viewer.zmags.com/publication/cc59823c?page=70"> Table 2: Oxidative DNA damage and apoptosis marke</a> <a title="EMJ 3.3 2018 page 71" href="http://viewer.zmags.com/publication/cc59823c?page=71"> Caspase-3, Caspase-8, Cytochrome c, and Soluble T</a> <a title="EMJ 3.3 2018 page 72" href="http://viewer.zmags.com/publication/cc59823c?page=72"> decrease favours graft maintenance. Other</a> <a title="EMJ 3.3 2018 page 73" href="http://viewer.zmags.com/publication/cc59823c?page=73"> ovarian carcinoma. J Ovarian Res. </a> <a title="EMJ 3.3 2018 page 74" href="http://viewer.zmags.com/publication/cc59823c?page=74"> Switching from Reference to Biosimilar Products: </a> <a title="EMJ 3.3 2018 page 75" href="http://viewer.zmags.com/publication/cc59823c?page=75"> INTRODUCTION The number of biosimilar medicines a</a> <a title="EMJ 3.3 2018 page 76" href="http://viewer.zmags.com/publication/cc59823c?page=76"> prescription may substitute the interchangeable p</a> <a title="EMJ 3.3 2018 page 77" href="http://viewer.zmags.com/publication/cc59823c?page=77"> has been observed in Central and Eastern Eu</a> <a title="EMJ 3.3 2018 page 78" href="http://viewer.zmags.com/publication/cc59823c?page=78"> nor patients knowing the assigned treatment. Swit</a> <a title="EMJ 3.3 2018 page 79" href="http://viewer.zmags.com/publication/cc59823c?page=79"> rates tended to increase in the more recen</a> <a title="EMJ 3.3 2018 page 80" href="http://viewer.zmags.com/publication/cc59823c?page=80"> same time, specific collaborative switchin</a> <a title="EMJ 3.3 2018 page 81" href="http://viewer.zmags.com/publication/cc59823c?page=81"> 25. Alten R et al. Preliminary real world </a> <a title="EMJ 3.3 2018 page 82" href="http://viewer.zmags.com/publication/cc59823c?page=82"> Knee Infection After Anterior Cruciate Ligame</a> <a title="EMJ 3.3 2018 page 83" href="http://viewer.zmags.com/publication/cc59823c?page=83"> between 0.4% and 2.0%, while arthroscopic pr</a> <a title="EMJ 3.3 2018 page 84" href="http://viewer.zmags.com/publication/cc59823c?page=84"> Graft contamination is a risk for </a> <a title="EMJ 3.3 2018 page 85" href="http://viewer.zmags.com/publication/cc59823c?page=85"> the definition of the distal edge of femur,</a> <a title="EMJ 3.3 2018 page 86" href="http://viewer.zmags.com/publication/cc59823c?page=86"> A Medial femoral condile ACL Medial PC</a> <a title="EMJ 3.3 2018 page 87" href="http://viewer.zmags.com/publication/cc59823c?page=87"> an improvement over their functional score b</a> <a title="EMJ 3.3 2018 page 88" href="http://viewer.zmags.com/publication/cc59823c?page=88"> One week after discharge, the patient had s</a> <a title="EMJ 3.3 2018 page 89" href="http://viewer.zmags.com/publication/cc59823c?page=89"> allografts more likely to get infected? A cohort </a> <a title="EMJ 3.3 2018 page 90" href="http://viewer.zmags.com/publication/cc59823c?page=90"> The Role of Nicotinamide Adenine Dinucleotide </a> <a title="EMJ 3.3 2018 page 91" href="http://viewer.zmags.com/publication/cc59823c?page=91"> can differentiate toward the T helper (Th) 1 or T</a> <a title="EMJ 3.3 2018 page 92" href="http://viewer.zmags.com/publication/cc59823c?page=92"> activity to the TNF inhibitor etanercep</a> <a title="EMJ 3.3 2018 page 93" href="http://viewer.zmags.com/publication/cc59823c?page=93"> POLY-ADP-RIBOSE POLYMERASE-1 IS INVOLVED IN INFLA</a> <a title="EMJ 3.3 2018 page 94" href="http://viewer.zmags.com/publication/cc59823c?page=94"> CD38 IS INVOLVED IN T REGULATORY CELL HOMEOSTASIS</a> <a title="EMJ 3.3 2018 page 95" href="http://viewer.zmags.com/publication/cc59823c?page=95"> Single doses of 100, 300, and 1,000 mg of NR prod</a> <a title="EMJ 3.3 2018 page 96" href="http://viewer.zmags.com/publication/cc59823c?page=96"> Different NAD+-consuming enzymes, such a</a> <a title="EMJ 3.3 2018 page 97" href="http://viewer.zmags.com/publication/cc59823c?page=97"> 34. Yu Q et al. SIRT1 and HIF1α signaling </a> <a title="EMJ 3.3 2018 page 98" href="http://viewer.zmags.com/publication/cc59823c?page=98"> OPENING DOORS TO EXPANDED POSSIBILITIES IN LEUKAE</a> <a title="EMJ 3.3 2018 page 99" href="http://viewer.zmags.com/publication/cc59823c?page=99"> Epstein–Barr Virus: A Biological Overview and </a> <a title="EMJ 3.3 2018 page 100" href="http://viewer.zmags.com/publication/cc59823c?page=100"> the USA and Europe.3 Geographical differences are</a> <a title="EMJ 3.3 2018 page 101" href="http://viewer.zmags.com/publication/cc59823c?page=101"> A B C D E F Figure 1: Ex</a> <a title="EMJ 3.3 2018 page 102" href="http://viewer.zmags.com/publication/cc59823c?page=102"> The importance of these latency types is that the</a> <a title="EMJ 3.3 2018 page 103" href="http://viewer.zmags.com/publication/cc59823c?page=103"> cell nuclei. The patients were elderly, had</a> <a title="EMJ 3.3 2018 page 104" href="http://viewer.zmags.com/publication/cc59823c?page=104"> are rare, representing an exclusion form fo</a> <a title="EMJ 3.3 2018 page 105" href="http://viewer.zmags.com/publication/cc59823c?page=105"> may appear concomitant to a neoplasm, for e</a> <a title="EMJ 3.3 2018 page 106" href="http://viewer.zmags.com/publication/cc59823c?page=106"> the pathology and oncology aspects of EBV infecti</a> <a title="EMJ 3.3 2018 page 107" href="http://viewer.zmags.com/publication/cc59823c?page=107"> acute lymphoblastic leukemia: </a> <a title="EMJ 3.3 2018 page 108" href="http://viewer.zmags.com/publication/cc59823c?page=108"> A Game of Clones: The Complex Interplay of Aplas</a> <a title="EMJ 3.3 2018 page 109" href="http://viewer.zmags.com/publication/cc59823c?page=109"> and systemic illnesses, such as infection a</a> <a title="EMJ 3.3 2018 page 110" href="http://viewer.zmags.com/publication/cc59823c?page=110"> 200–400 per million per year.6 The highly v</a> <a title="EMJ 3.3 2018 page 111" href="http://viewer.zmags.com/publication/cc59823c?page=111"> variant of MDS. While hypoMDS accounts for 10% of</a> <a title="EMJ 3.3 2018 page 112" href="http://viewer.zmags.com/publication/cc59823c?page=112"> with the expansion of a residual HSC possessing b</a> <a title="EMJ 3.3 2018 page 113" href="http://viewer.zmags.com/publication/cc59823c?page=113"> Clonal impact on haematopoiesis PNH CHIP </a> <a title="EMJ 3.3 2018 page 114" href="http://viewer.zmags.com/publication/cc59823c?page=114"> cells in patients with AA or MDS is an important </a> <a title="EMJ 3.3 2018 page 115" href="http://viewer.zmags.com/publication/cc59823c?page=115"> CONCLUSION Traditionally considered to be dis</a> <a title="EMJ 3.3 2018 page 116" href="http://viewer.zmags.com/publication/cc59823c?page=116"> What's New e-Cigarette Health Warnings e-CIGARET</a> <a title="EMJ 3.3 2018 page 117" href="http://viewer.zmags.com/publication/cc59823c?page=117"> Mechanism of Fibrosis Discovered: A Potential The</a> <a title="EMJ 3.3 2018 page 118" href="http://viewer.zmags.com/publication/cc59823c?page=118"> What's New Epigenetic Reprogramming in Ischaemic</a> <a title="EMJ 3.3 2018 page 119" href="http://viewer.zmags.com/publication/cc59823c?page=119"> Touch-Free Monitoring of Heart Sounds RADAR-BASED</a> <a title="EMJ 3.3 2018 page 120" href="http://viewer.zmags.com/publication/cc59823c?page=120"> Never miss an update again. J</a>